COVID-19 and inflammatory bowel disease: A pathophysiological assessment.
Biomed Pharmacother
; 135: 111233, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1009323
ABSTRACT
Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, has led to the ongoing global pandemic. Although most patients experience no or only mild symptoms, some patients can develop severe illness, such as progressive pneumonia, acute respiratory distress syndrome, secondary hemophagocytic lymphohistiocytosis and multiple organ failure caused by cytokine release syndrome. A majority of COVID-19 patients also develop gastrointestinal symptoms. These can present special challenges to the management of patients with inflammatory bowel disease (IBD) due to potential interactions between the immune response related to SARS-CoV-2 infection and dysregulated immunity associated with IBD. In this context, the pathogenesis of COVID-19 is reviewed in order to address these questions regarding immune interactions between COVID-19 and IBD.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
COVID-19
/
Immunity
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Biomed Pharmacother
Year:
2021
Document Type:
Article
Affiliation country:
J.biopha.2021.111233
Similar
MEDLINE
...
LILACS
LIS